Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Latuda

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

US jury says Takeda and Lilly must pay $9bn in Actos damages

Court says companies covered up cancer risks of diabetes drug

- PMLiVE

EU approval for Takeda’s schizophrenia drug

Latuda said to have improved side effect profile compared to other treatments

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Double win for J&J’s schizophrenia franchise

Pharma company wins appeal against $1.2bn fine and Risperdal follow-up proves itself in trial

- PMLiVE

Takeda promotes Giles Platford

Appoints him head of commercial operations, emerging markets

- PMLiVE

Abilify Maintena launches in Europe

Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Takeda CEO admits to Blopress mis-marketing

Campaign used graph indicating drug was superior to Pfizer’s Norvasc

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links